Journal of Leukocyte Biology

J Immunol. 2025 Oct 28:vkaf285. doi: 10.1093/jimmun/vkaf285. Online ahead of print. ABSTRACT The β2-adrenergic receptor (β2AR) signaling suppresses the activation of key inflammatory genes in Toll-like receptor (TLR) stimulated macrophages, but Il1b transcription is activated by β2AR signaling. The β2ARs potently activate protein kinase A and CREB, but other signaling pathways can also be activated, … Read more

J Immunol. 2025 Oct 28:vkaf288. doi: 10.1093/jimmun/vkaf288. Online ahead of print. ABSTRACT The risk of developing melanoma increases with age. Although immune checkpoint blockade (ICB) therapy has shown considerable success, a significant portion of melanoma patients either fail to respond to ICB or eventually develop resistance. This leads to the urgent need for exploring novel … Read more

J Immunol. 2025 Oct 28:vkaf279. doi: 10.1093/jimmun/vkaf279. Online ahead of print. ABSTRACT Natural killer (NK) cells play essential roles in immunity, but their limited infiltration into solid tumors restricts their therapeutic potential. Here, we identify fibroblast activation protein (FAP), previously thought to be largely fibroblast-restricted, as a novel surface-expressed protease on human NK cells. Using … Read more

Nature Reviews Immunology, Published online: 28 October 2025; doi:10.1038/s41577-025-01230-wThis Perspective presents a framework of ‘structural immunity’ that positions immune cells as architects of tissue structure. Beyond their role…

Background Immune checkpoint therapies targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been met with limited clinical responses in the treatment of patients of varying cancer types. Current US Food and Drug …